TMCnet News
Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, 2018 at 10:45 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics' website at www.seattlegenetics.com in the Investors section. About Seattle Genetics Seattle Genetics is an innovative biotechology company dedicated to improving the lives of people with cancer through targeted therapies. The company's industry-leading antibody-drug conjugate (ADC (News - Alert)) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS® (brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas. The company is also advancing a robust pipeline of novel therapies for solid tumors and blood-related cancers designed to address significant unmet medical needs and improve treatment outcomes for patients. More information can be found at www.seattlegenetics.com and follow @SeattleGenetics on Twitter (News - Alert).
View source version on businesswire.com: http://www.businesswire.com/news/home/20180313005322/en/ |
